Response Pharmaceuticals is developing its lead asset, RDX-002, a first-in-class weight management and cardiometabolic health drug with confirmed efficacy and safety in >550 subjects. All programs are in Phase 2 clinical development. 

Our initial focus is on helping underserved patient populations taking antipsychotic medications for disabling mental illnesses to combat weight gain and metabolic dysregulation associated with these treatments. Antipsychotic-induced weight gain (AIWG) is a drug-induced epidemic within the already vulnerable population of patients with severe mental illness, and is contributing to a growing mortality gap between people with mental illness and the general population. 

Additionally, RDX-002 is being evaluated in other settings in which clinically significant weight gain and/or adverse metabolic changes are prevalent.

Response Pharmaceuticals

Org chart

Teams

Offices